Court Tosses Suit Over Lundbeck's Purchase Of Two Drugs Used In Premature Infants
This article was originally published in The Pink Sheet Daily
Executive Summary
Federal judge finds NeoProfen and Indocin IV are not in the same product market; FTC and Minnesota filed suit after Lundbeck raised the price of Indocin, then the only approved drug, by 1,300%.
You may also be interested in...
Mallinckrodt, FTC And The Antitrust Risks Of Pipeline Acquisitions
Acthar case could discourage firms looking to enhance franchises by acquiring drugs in development after FTC alleges firm purchased a would-be competitor to keep it off the US market. Is this something else we can blame on Martin Shkreli?
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.
Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?
The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.